Comparative safety of denosumab and romosozumab in osteoporosis: an analysis based on the FDA adverse event reporting system database - PubMed
5 hours ago
- #pharmacovigilance
- #osteoporosis
- #immunology
- Denosumab and romosozumab are biological agents used to treat osteoporosis, with potential immunomodulatory effects.
- The study compared their safety using the FDA Adverse Event Reporting System (FAERS), focusing on immune-related adverse reactions.
- Denosumab showed long-term cumulative risks, particularly in musculoskeletal and metabolic disorders.
- Romosozumab demonstrated acute and severe cardiovascular risks, including coronary artery disease and heart failure.
- Denosumab was associated with osteoimmune complications like noninfectious gingivitis, while romosozumab's immune-related risks were minor injection-site reactions.
- The study highlights distinct safety profiles for each drug, suggesting the need for personalized therapy approaches.